Loading...
Docoh

Blueprint Medicines (BPMC)

Utility
RAF1 Fusions
30 Jun 22
The invention provides to RAF1 gene fusions, RAF1 fusion proteins, and fragments of those genes and polypeptides.
Nicolas STRANSKY, Joseph L. Kim
Filed: 30 Sep 21
Utility
Ret Inhibitor for Use In Treating Cancer Having a Ret Alteration
9 Jun 22
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Erica Evans Raab, Beni B. Wolf
Filed: 16 Jul 21
Utility
Inhibitors of RET
22 Mar 22
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Filed: 29 Jan 20
Utility
RET inhibitor for use in treating cancer having a RET alteration
15 Mar 22
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Erica Evans Raab, Beni B. Wolf
Filed: 18 Dec 20
Utility
PRKC fusions
1 Mar 22
The invention provides PRKC gene fusions, PRKC fusion proteins, and fragments of those genes and polypeptides.
Nicolas Stransky, Joseph L. Kim
Filed: 16 Jul 19
Utility
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
1 Feb 22
Jason D. Brubaker, Paul E. Fleming, Joseph L. Kim, Brett Williams, Brian L. Hodous
Filed: 18 Oct 18
Utility
Avapritinib Resistance of Kit Mutants
13 Jan 22
The disclosure includes methods of treating a patient suffering from a malignant disease driven by activating mutations in KIT, said method comprising: (a) obtaining a biological sample from the patient; (b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample; and (c) administering a KIT inhibitor to the patient if the mutation is not detected.
Oleg Schmidt-Kittler
Filed: 11 Nov 19
Utility
Inhibitors of the Fibroblast Growth Factor Receptor
11 Nov 21
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
Filed: 24 Nov 20
Utility
Treatment of Egfr-mutant Cancer
7 Oct 21
Disclosed herein are methods for treating an EGFR-mutant cancer in a patient in need thereof by administering to the patient a therapeutically effective amount of at least one RET inhibitor (e.g., Compound 1 and/or pharmaceutically acceptable salts thereof) and a therapeutically effective amount of at least one EGFR inhibitor (e.g., osimertinib and/or pharmaceutically acceptable salts thereof), as well as combination therapies including at least one RET inhibitor and at least one EGFR inhibitor.
Aaron Hata, Lecia Sequist, Beni B. Wolf
Filed: 9 Aug 19
Utility
Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
23 Sep 21
This disclosure relates to combinations of RET inhibitors and inhibitors of mTORC1 and their use in the treatment of various cancers mediated by aberrant RET activity.
Erica Evans Raab, Rami Rahal
Filed: 15 May 18
Utility
Compositions Useful for Treating Disorders Related to Kit
16 Sep 21
Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
Filed: 14 Oct 20
Utility
Compounds and compositions useful for treating disorders related to NTRK
13 Jul 21
This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.
Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
Filed: 31 Jul 19
Utility
Compounds and compositions useful for treating disorders related to NTRK
29 Jun 21
Steven Mark Wenglowsky, Natasja Brooijmans, Chandrasekhar V. Miduturu, Neil Bifulco, Jr.
Filed: 3 Jul 18
Utility
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
22 Jun 21
Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
Filed: 29 Mar 18
Utility
Crystalline Forms of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE and Methods of Making
20 May 21
Joshua D. Waetzig, Brenton Mar, Brian Heinrich, Gordon Wilkie, Lauren MacEachern
Filed: 20 Jan 21
Utility
Ret Inhibitor for Use In Treating Cancer Having a Ret Alteration
8 Apr 21
Disclosed herein is the treatment of a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 300 mg to 400 mg of the selective RET inhibitor once daily.
Erica Evans Raab, Beni B. Wolf
Filed: 3 Apr 19
Utility
Ret Inhibitor for Use In Treating Cancer Having a Ret Alteration
8 Apr 21
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Erica Evans Raab, Beni B. Wolf
Filed: 18 Dec 20
Utility
Ret Inhibitor for Use In Treating Cancer Having a Ret Alteration
25 Mar 21
Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.
Erica Evans Raab, Beni B. Wolf
Filed: 2 Oct 20
Utility
Inhibitors of Ret
30 Dec 20
Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
Filed: 28 Jan 20
Utility
Inhibitors of the fibroblast growth factor receptor
28 Dec 20
Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
Filed: 18 Feb 19
Patents are sorted by USPTO publication date, most recent first